Consort Medical PLC Incident at the Aesica Cramlington API Facility (4554F)
July 15 2019 - 2:00AM
UK Regulatory
TIDMCSRT
RNS Number : 4554F
Consort Medical PLC
15 July 2019
Consort Medical plc
15 July 2019
Incident at the Aesica Cramlington API Facility
Consort Medical plc (LSE: CSRT) ("Consort" or "Consort
Medical"), a leading developer and manufacturer of drugs and
premium drug delivery devices, announces that there was a recent
incident in its Cramlington manufacturing facility. While no
injuries were incurred in the incident, a small area of the
operating plant was damaged by the rapid thermal degradation of a
chemical resulting in the expulsion of material and contamination
of the facility.
The safety of our employees is our absolute priority and we have
suspended all similar manufacturing processes as we determine the
cause of the incident. We are being supported in this by a
specialist decontamination company and process safety experts. They
will investigate the causes and compile an independent report. We
are also working closely with the local regulatory authorities.
The financial impact can not be accurately quantified at this
stage as it will depend on a number of factors including the timing
and results of the investigation, the completion of remediation
work and future production activities. However, our initial
expectation is that the Group's profit is likely to be negatively
impacted by between GBP3 million to GBP5 million in the current
financial year due to our current estimate of the anticipated
disruption from this incident.
Enquiries:
Consort Medical Tel: +44 (0) 1442 867920
Jonathan Glenn - Chief Executive Officer
Paul Hayes - Chief Financial Officer
FTI Consulting Tel: +44 (0) 20 3727
1000
Ben Atwell / Simon Conway
About Consort Medical plc
Consort Medical plc is a leading, global, single source pharma
services drug and delivery device company. We are at the leading
edge of innovation and we are committed to investing in patient,
clinician and customer driven innovation to create new treatments,
new markets and new opportunities.
Our businesses:
Bespak is a global market leader in the manufacture of drug
delivery devices for pharmaceutical partner companies, including
respiratory, nasal, injectables and ocular products, and the
manufacture of devices for the point of care diagnostics market.
www.bespak.com.
Aesica is a leading provider of finished dose and active
pharmaceutical ingredient (API) development and manufacturing
services to pharmaceutical partners. www.aesica-pharma.com.
We employ approximately 2,000 people globally of which
approximately 1,400 are located in the UK. We have UK facilities in
King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington,
Queenborough and Hemel Hempstead, German facilities in Monheim and
Zwickau and a facility in Pianezza, Italy. Consort Medical is a
public company quoted on the premium list of the London Stock
Exchange (LSE: CSRT). www.consortmedical.com.
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCDGGDRRXBBGCS
(END) Dow Jones Newswires
July 15, 2019 02:00 ET (06:00 GMT)
Consort Medical (LSE:CSRT)
Historical Stock Chart
From Apr 2024 to May 2024
Consort Medical (LSE:CSRT)
Historical Stock Chart
From May 2023 to May 2024